Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Whyme16on Mar 16, 2022 9:41am

135 Views

Post# 34517920

MORE than 3 weeks since comments from HREC and yet Nothing!!

Are these company's actions even legal?? They have clearly misled investors OVER & OVER with empty promises and now the warrants are about to be expired..... Feb 22nd NR stated the respond will be provided later the SAME WEEK!!

This delay GUARANTIES that the warrants will become useless... WHO aside from Salzman benefits from this??

We are in held in absolute dark and none of teh puppets are there to say where the f... is Bob??

<< Previous

Bullboard Posts

Next >>

FLYHT and WestJet partner on weather forecasting